<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="3" ids="16335">Adenosine</z:chebi> is a potent biological mediator, the concentration of which increases dramatically following brain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>During <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, <z:chebi fb="3" ids="16335">adenosine</z:chebi> is in a concentration range (muM) that stimulates <z:hpo ids='HP_0000001'>all</z:hpo> four <z:chebi fb="3" ids="16335">adenosine</z:chebi> receptor subtypes (A(1), A(2A), A(2B) and A(3)) </plain></SENT>
<SENT sid="2" pm="."><plain>In recent years, evidence has indicated that the A(2A) receptor subtype is of critical importance in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We have previously shown that 24 h after medial cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo), A(2A) receptors up-regulate on neurons and microglia of ischaemic striatum and cortex and that subchronically administered <z:chebi fb="3" ids="16335">adenosine</z:chebi> A(2A) receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> protect against brain damage and neurological deficit and reduce activation of p38 <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK) in microglial cells </plain></SENT>
<SENT sid="4" pm="."><plain>The mechanisms by which A(2A) receptors are noxious during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> still remain elusive </plain></SENT>
<SENT sid="5" pm="."><plain>The objective of the present study was to investigate whether the <z:chebi fb="3" ids="16335">adenosine</z:chebi> A(2A) <z:chebi fb="68" ids="48706">antagonist</z:chebi> SCH58261 affects JNK and MEK1/ERK MAPK activation </plain></SENT>
<SENT sid="6" pm="."><plain>A further aim was to investigate cell types expressing activated JNK and MEK1/ERK MAPK after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>We hereby report that the selective <z:chebi fb="3" ids="16335">adenosine</z:chebi> A(2A) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, SCH58261, administered subchronically (0.01 mg/kg i.p) 5 min, 6 and 20 h after MCAo in male Wistar rats, reduced JNK MAPK activation (immunoblot analysis: phospho-JNK54 isoform by 81% and phospho-JNK46 isoform by 60%) in the ischaemic striatum </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty-four hours after MCAo, the Olig2 transcription factor of oligodendroglial progenitor cells and mature oligodendrocytes was highly expressed in cell bodies in the ischaemic striatum </plain></SENT>
<SENT sid="9" pm="."><plain>Immunofluorescence staining showed that JNK MAPK is maximally expressed in Olig2-stained oligodendrocytes and in a few NeuN stained neurons </plain></SENT>
<SENT sid="10" pm="."><plain>Striatal cell fractioning into nuclear and extra-nuclear fractions demonstrated the presence of Olig2 transcription factor and JNK MAPK in both fractions </plain></SENT>
<SENT sid="11" pm="."><plain>The A(2A) <z:chebi fb="68" ids="48706">antagonist</z:chebi> reduced striatal Olig 2 transcription factor (immunoblot analysis: by 55%) and prevented myelin disorganization, assessed by myelin-associated <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> staining </plain></SENT>
<SENT sid="12" pm="."><plain>Twenty-four hours after MCAo, ERK1/2 MAPK was highly activated in the ischaemic striatum, mostly in microglia, while it was reduced in the ischaemic cortex </plain></SENT>
<SENT sid="13" pm="."><plain>The A(2A) <z:chebi fb="68" ids="48706">antagonist</z:chebi> did not affect activation of the ERK1/2 pathway </plain></SENT>
<SENT sid="14" pm="."><plain>The efficacy of A(2A) receptor antagonism in reducing activation of JNK MAPK in oligodendrocytes suggests a mechanism of protection consisting of <z:hpo ids='HP_0100699'>scarring</z:hpo> oligodendrocyte inhibitory molecules that can hinder myelin reconstitution and neuron functionality </plain></SENT>
</text></document>